StockData
Autolus Therapeutics plc logo

Autolus Therapeutics plc (AUTL) stock

AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3020% below fair value
$1.09−0.05 (-4.39%)

Close on Nov 17, 2026Market cap $290.12MP/E –Yield –

Autolus Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Autolus Therapeutics's price to sales ratio was 2.8× on Nov 11, 2026, against 7.3× a year earlier. Over the last 4 years it ranged from 2.8× to 462.7×, with a median of 183.5×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20262.8×−7.6
2025Dec 31, 202510.4×−154.5
2021Jan 29, 2021164.8×−35.7
2020Dec 31, 2020200.5×−95.6
2019Dec 31, 2019296.1×+64.0
2018Oct 31, 2018232.0×–

More Autolus Therapeutics figures

See a number that looks wrong?